purpleDx App for Remote Lung Monitoring

electronRx, a leading digital medicine and biomarker company that is transforming healthcare through pulmonary innovation, announced today that it will introduce purpleDx, a cardiac evaluation app developed to medical device standards, at CES 2025 in Las Vegas, USA, from January 7 to 10. The system allows chronic respiratory disease (CRD) patients to detect and monitor digital biomarkers of lung function at home, while doctors receive real-time data to tailor treatment strategies and enhance patient outcomes.

purpleDx is a smartphone app and clinical dashboard that helps doctors detect, monitor, and treat pulmonary disorders such asthma, chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension. It was created in partnership with numerous respiratory clinics and the company’s latest charity partner, the European pulmonary hypertension association (PHA Europe).

The scalable system uses digital biomarkers created by mobile device sensors to analyze physiological cardiopulmonary metrics like heart rate, breathing rate, and tidal volume. Healthcare practitioners can obtain physiological data in real time via the clinical dashboard, allowing them to remotely monitor patients’ lung function and change treatment plans as needed to improve drug efficacy. Remote monitoring also ensures that patients only need to visit the hospital when absolutely necessary, saving them time and energy while also contributing to the efficiency of healthcare delivery.

CRDs are the third greatest cause of death worldwide. electronRx’s patented suite of digital solutions is focused to improve the lives of patients with respiratory issues by employing smartphone technology to evaluate changes in cardiac and pulmonary functions, allowing them to make educated interventions. These digital apps are embedded into iPhones and use the camera to capture and monitor blood flow around the face, which is imperceptible to the naked eye. A typical 30-60 second measurement collects millions of data points, which can then be translated into digital biomarkers to measure a variety of physiological parameters.

Integrating digital biomarker monitoring with prescribed medications embodies a revolutionary approach to healthcare management. Our purpleDx technology transforms a mobile phone into a powerful tool that will not only enable patients to measure and quantify lung health but share these invaluable and potentially life-saving insights with their healthcare providers. This will empower them to manage chronic diseases more effectively and tailor treatments for individuals, leading to enhanced therapeutic outcomes.

We’re incorporating the latest clinical insights and data into purpleDx to ensure our platform remains at the forefront of technological innovation and continues to drive advancements in the management and treatment of CRDs worldwide.

We are incredibly grateful to all of our collaborators, particularly the patients, for their support and look forward to demonstrating electronRx’s purpleDx technology at CES next month.”

Dr Bipin Patel, CEO and Founder, electronRx